The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
EMA: Treatment for adult patients in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma - FDA: Treatment for adult patients in combination with durvalumab with unresectable hepatocellular carcinoma HIMALAYA
Gastrointestinal Cancers
Hepatobiliary Cancers - Hepatocellular Carcinoma
-
HIMALAYA
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Cemiplimab
-
Investigator's choice of ChT
Indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapyEMPOWER-Cervical 1
Gynaecological Malignancies
Cervical Cancer
-
EMPOWER-Cervical 1
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
FOLFIRINOX
-
Gemcitabine
First-line metastatic pancreatic cancer in patients with good performance statusPRODIGE 4/ACCORD 11
Gastrointestinal Cancers
Pancreatic cancer
-
PRODIGE 4/ACCORD 11
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Pembrolizumab
-
Docetaxel
Locally advanced or metastatic NSCLC with PD-L1 expression ≥1% TPS after ≥1 prior ChT regimen. Patients with EGFR or ALK-positive tumour mutations should also have received targeted therapy (2 mg/kg and 10mg/kg pooled data)KEYNOTE-010
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 ≥1%
KEYNOTE-010
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Pembrolizumab
-
Docetaxel
Locally advanced or metastatic NSCLC with PD-L1 expression ≥1% TPS after ≥1 prior ChT regimen. Patients with EGFR or ALK-positive tumour mutations should also have received targeted therapy (2 mg/kg and 10mg/kg pooled data)KEYNOTE-010
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 ≥50%
KEYNOTE-010
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Nivolumab
-
Docetaxel
Locally advanced or metastatic squamous NSCLC after prior ChTCheckMate 017
Thoracic Malignancies
Non-small-cell Lung Cancer - Squamous cell
-
CheckMate 017
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Nivolumab
-
Docetaxel
Locally advanced or metastatic squamous NSCLC after prior ChTCheckMate 057
Thoracic Malignancies
Non-small-cell Lung Cancer
-
CheckMate 057
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Afatinib
-
Cisplatin + pemetrexed
As monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s) - Del19/L858R pre-planned subgroup analysisLUX - Lung 3
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
LUX - Lung 3
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Pembrolizumab
-
Platinum-based chemotherapy
First line treatment of mNSCLC with tumour PD-L1 expression ≥50% TPS with no EGFR or ALK positive tumour mutationsKEYNOTE-24
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 ≥50%
KEYNOTE-24
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Dab/Tram (dabrafenib and trametinib)
-
Vemurafenib
Dabrafenib in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutationCOMBI-v
Skin Cancers
Cutaneous Melanoma
BRAF V600
COMBI-v
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Nivolumab
-
Everolimus
As monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adultsCheckMate025
Genitourinary Cancers
Renal cell cancer
-
CheckMate025
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Atezolizumab
-
Docetaxel
As monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapyOAK
Thoracic Malignancies
Squamous or non-squamous non-small-cell lung cancer
-
OAK
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Ribociclib
Endocrine therapy
Placebo + endocrine therapy
Treatment of women with HR+, HER2 negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.. In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone‑releasing hormone (LHRH) agonist.MONALEESA-7
Breast Cancer
Breast Cancer
HR+ HER2-
MONALEESA-7
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Binimetinib
Encorafenib
Vemurafenib
In combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutationCOLUMBUS
Skin Cancers
Cutaneous Melanoma
BRAF V600
COLUMBUS
A
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a/F1
5
A
Nivolumab
-
Investigator choice (methotrexate or cetuximab or docetaxel)
As monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapyCheckMate141
Head and neck cancer
Squamous cell
-
CheckMate141
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Atezolizumab
Bevacizumab
Sorafenib
Advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy IMbrave150
Gastrointestinal Cancers
Hepatobiliary Cancers - Hepatocellular Carcinoma
-
IMbrave150
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Atezolizumab
-
Platinum-based chemotherapy
First-line treatment of patients with high PD-L1 expression ≥50% TC or ≥10% IC and who do not have EGFR mutant or ALK-positive NSCLCIMpower110
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 expression ≥50% TC or ≥10% IC
IMpower110
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.